Sridhar Goud Nerella, Ahana Bhattacharya, Pavitra S Thacker, Sanam Tulja
Journal: Expert opinion on therapeutic patents 2022;32(4):455-473
PMID: 35072592
INTRODUCTION
Fluorine-18 is a promising radionuclide for developing novel PET radiotracers due to its characteristic features such as convenient half-life, metabolic stability, good imaging properties, and easy access to various clinical PET centers. Currently, many F-radiotracers are available to study disease status in the fields of oncology, cardiology, and neurology.
AREAS COVERED
In this review, the authors have covered patents and research papers of F-radiotracers with clinical applications in various diseases using PET modality since 2015 until the present through SciFinder database.
EXPERT OPINION
Despite other PET radionuclides C, N, and O, the F is widely used for radiotracer development because of maximum half-life of 109.8 min. The major limitations of PET radiotracer development include low radiochemical yields and less regioselectivity of the radiofluorination reactions. Therefore, various synthetic methodologies were developed for radiofluorination nucleophilic, electrophilic with specific precursors, transition metal mediated, and prosthetic groups mediated radiofluorination. Automated radiosynthesis methods have been adapted for easy and convenient synthesis of various F-radiotracers, whereas the PET provides functional information about a disease condition through its pharmacology and physiological processes , and it is also an essential tool in drug discovery to study therapeutic drug development, and pharmacokinetic profiles.
Full Text Sources:
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.